![Rafi Kazandjian](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Career history of Rafi Kazandjian
Former positions of Rafi Kazandjian
Companies | Position | Start | End |
---|---|---|---|
Eyevensys SAS
![]() Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France. | Director/Board Member | 21/05/2014 | - |
Chief Executive Officer | 21/05/2014 | 11/12/2017 | |
Chairman | 21/05/2014 | - | |
President | 21/05/2014 | 11/12/2017 | |
Immutep SAS
![]() Immutep SAS Pharmaceuticals: MajorHealth Technology Immutep SAS specializes in biotechnology research and development. It develops immunotherapy treatments for cancer and autoimmune diseases. The company was founded by Frédéric Triebel on October 17, 2001 and is headquartered Orsay, France. | Director/Board Member | - | 17/11/2015 |
Statistics
International
France | 3 |
Operational
Director/Board Member | 2 |
Chief Executive Officer | 1 |
Chairman | 1 |
Sectoral
Health Technology | 2 |
Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 2 |
---|---|
Immutep SAS
![]() Immutep SAS Pharmaceuticals: MajorHealth Technology Immutep SAS specializes in biotechnology research and development. It develops immunotherapy treatments for cancer and autoimmune diseases. The company was founded by Frédéric Triebel on October 17, 2001 and is headquartered Orsay, France. | Health Technology |
Eyevensys SAS
![]() Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Eyevensys SAS develops non-viral gene therapy process for the treatment of ocular illnesses. The firm's process enables prolonged production of all therapeutic proteins through electrotransfer. Its product, the single-used device is designed for treating ocular illnesses. The company was founded by Francine Behar-Cohen on December 8, 2008 and is headquartered in Paris, France. | Commercial Services |
- Stock Market
- Insiders
- Rafi Kazandjian
- Experience